Search for predicvite factors of anti-PD-1 antibody, pembrolizumab
Not Applicable
- Conditions
- advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000030284
- Lead Sponsor
- Tochigi Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Not provided
Exclusion Criteria
1)Positive HBS-ag and/or HCV-ab 2)Positive HIV-ab 3)the primary doctor judging inappropriate for entry
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Detection of gelsolin immunocomplex
- Secondary Outcome Measures
Name Time Method 1) Response rate of pembrolizumab 2) Detection rate of Gelsolin immune complex 3) Progression free survival (PFS) of pembrolizumab 4) Number of immune complexes in serum of pembrolizumab administration cases 5) Number of Gelsolin immune complexes in serum of pembrolizumab administration cases